ArticleAmerican journal of translational research2019
LINC01234 promotes multiple myeloma progression by regulating miR-124-3p/GRB2 axis.
Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Heterogeneity study on MiRNA expression in islet cells of rat pancreatic head and tail.BMC medical genomics · 2025Article
- LncRNA EBLN3P/microRNA-323a-3p/EphA1 axis affects the biological function of hepatocellular carcinoma cells.Discover oncology · 2025Article
- Exosome miRNAs profiling in serum and prognostic evaluation in patients with multiple myeloma.Blood science (Baltimore, Md.) · 2023Article
- Long non‑coding RNAs in multiple myeloma (Review).International journal of oncology · 2023Review
- GRB2 dimerization mediated by SH2 domain-swapping is critical for T cell signaling and cytokine production.Scientific reports · 2023Article
- Long noncoding RNA LINC01234 promotes hepatocellular carcinoma progression through orchestrating aspartate metabolic reprogramming.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Tribbles homolog 3 contributes to high glucose-induced injury in retinal pigment epithelial cells via binding to growth factor receptor-bound 2.Bioengineered · 2022Article
- The LncRNA RP11-301G19.1/miR-582-5p/HMGB2 axis modulates the proliferation and apoptosis of multiple myeloma cancer cells via the PI3K/AKT signalling pathway.Cancer gene therapy · 2022Article
- Identifying the Effect of COVID-19 Infection in Multiple Myeloma and Diffuse Large B-Cell Lymphoma Patients Using Bioinformatics and System Biology.Computational and mathematical methods in medicine · 2022Article
- Review
- Long Non-coding RNA RP11-395G23.3 Acts as a Competing Endogenous RNA of miR-124-3p to Regulate ROR1 in Anaplastic Thyroid Carcinoma.Frontiers in genetics · 2021Article
- Long Noncoding RNA LUCAT1 Promotes Multiple Myeloma Cell Growth by Regulating the TGF-β Signaling Pathway.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
LncRNA is gradually considered as a vital regulator in various physiological and pathological processes. Recently, the role of LINC01234 in several cancers has been reported. However, the function and underlying regulatory mechanism of LINC01234 in multiple myeloma (MM) remain unclear. Our results indicated that LINC01234 was over-expressed in tumor tissues of MM patients, and LINC01234 down-regulation remarkably inhibited cell proliferation, cycle progression and promoted cell apoptosis in MM cells. Mechanistic studies revealed that LINC01234 could sponge miR-124-3p and decreased its expression, thereby up-regulated the protein level of miR-124-3p's targets growth factor receptor-bound protein 2 (GRB2). Additionally,
Indexed as
Identifiers
31737211PMC6834521W2996650031What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.